Updates on pathogen inactivation of plasma using Theraflex methylene blue system

Abstract Methylene blue (MB) treated plasma has been in clinical use for 15 years. The current Theraflex MB-Plasma system has a number of improved features compared with the original Springe methodology. This article gives an overview of processing methodology and recent developments, pathogen inact...

Full description

Saved in:
Bibliographic Details
Published inTransfusion and apheresis science Vol. 38; no. 3; pp. 271 - 280
Main Authors Seghatchian, Jerard, Walker, Wolfram H, Reichenberg, Stefan
Format Journal Article
LanguageEnglish
Published England Elsevier Ltd 01.06.2008
Subjects
Blood Proteins - chemistry
Disinfection - instrumentation
Disinfection - methods
Hematology, Oncology and Palliative Medicine
Humans
Methylene Blue - chemistry
Plasma
Protein Stability
Safety
Online AccessGet full text

Cover

More Information
Summary:Abstract Methylene blue (MB) treated plasma has been in clinical use for 15 years. The current Theraflex MB-Plasma system has a number of improved features compared with the original Springe methodology. This article gives an overview of processing methodology and recent developments, pathogen inactivation capacity, pharmacokinetics and toxicology, effects on plasma proteins and storage stability, clinical experience and future perspectives. Emphasises will be placed on most recent literature and updated information available.
ISSN:1473-0502
1878-1683
DOI:10.1016/j.transci.2008.04.004